Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cartesian Therapeutics, Inc. - Common Stock (NQ:RNAC)

10.64 +0.64 (+6.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cartesian Therapeutics, Inc. - Common Stock

Cartesian (RNAC) Q2 Revenue Drops 99%
Via The Motley Fool
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027. 
Via Benzinga
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
U.S. stock futures were volatile on Wednesday after the equities reversed gains on Tuesday following Donald Trump's 104% tariff on China. 
Via Benzinga
Topics Government World Trade
Why Venus Concept Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients
Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025. 
Via Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
The company is the first to test a CAR-T drug against a placebo in patients with an autoimmune disease. 
Via Investor's Business Daily
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant improvements in MG Composite scores with a favorable safety profile. The... 
Via Benzinga
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts
SolarEdge layoffs are coming for 16% of the company's workers as it prepares to reduce its total headcount by 900 employees. 
Via InvestorPlace
Topics Workforce
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.